| Particulars (Rupees in Crores.) | Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 |
|---|---|---|---|---|---|
Gross Sales | 16,629.91 | 14,761.23 | 11,939.68 | 12,328.29 | 11,167.72 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 16,629.91 | 14,761.23 | 11,939.68 | 12,328.29 | 11,167.72 |
Other Operating Income | 410.86 | 288.8 | 271.9 | 194.16 | 212.5 |
Other Income | 138.87 | 90.92 | 36.09 | 127.05 | 90.19 |
Total Income | 17,179.64 | 15,140.95 | 12,247.67 | 12,649.5 | 11,470.41 |
Total Expenditure | 13,078.63 | 12,236.36 | 10,991.23 | 12,503.89 | 9,531.85 |
PBIDT | 4,101.01 | 2,904.59 | 1,256.44 | 145.61 | 1,938.56 |
Interest | 205.77 | 240.32 | 181.75 | 101.3 | 108.8 |
PBDT | 3,895.24 | 2,664.27 | 1,074.69 | 44.31 | 1,829.76 |
Depreciation | 776.08 | 739.71 | 616.7 | 1,331.52 | 671.69 |
Minority Interest Before NP | 0 | 0 | 0 | 0 | 0 |
Tax | 709.58 | 527.81 | 216.77 | 74.94 | 417.82 |
Deferred Tax | -114.3 | -170.6 | 35.92 | -364.52 | -23.31 |
Reported Profit After Tax | 2,523.88 | 1,567.35 | 205.3 | -997.63 | 763.56 |
Minority Interest After NP | 14.78 | 12.3 | 11.18 | 12.43 | 7.39 |
Net Profit after Minority Interest | 2,509.1 | 1,555.05 | 194.12 | -1,010.06 | 756.17 |
Extra-ordinary Items | 0 | 0 | 0 | 0 | 0 |
Adjusted Profit After Extra-ordinary item | 2,509.1 | 1,555.05 | 194.12 | -1,010.06 | 756.17 |
EPS (Unit Curr.) | 55.02 | 34.17 | 4.27 | -22.25 | 16.69 |
Book Value (Unit Curr.) | 0 | 0 | 0 | 0 | 0 |
Dividend (%) | 0 | 0 | 0 | 0 | 0 |
Equity | 91.25 | 91.07 | 90.96 | 90.84 | 90.7 |
Public Shareholding (Number) | 0 | 0 | 0 | 0 | 0 |
Public Shareholding (%) | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
PBIDTM(%) | 24.66 | 19.67 | 10.52 | 1.18 | 17.35 |
PBDTM(%) | 23.42 | 18.04 | 9 | 0.35 | 16.38 |
PATM(%) | 15.17 | 10.61 | 1.71 | -8.09 | 6.83 |
The drug will be manufactured at Lupin's facility in Nagpur, India, and the company has announced plans for a near-term launch in the U.S. market.
The clearance is on the back of a four-day USFDA inspection between June 10 and June 13, 2024.
The acquisition enhances Lupin’s portfolio of branded medicines and is aimed at furthering the company’s commitment to providing affordable and sustainable healthcare solutions.
Lupin said the tablets would be made at its Goa facility, which would bolster its global manufacturing capabilities and continued dedication to delivering affordable medications.
Here are some of the stocks that may see significant price movement today: IREDA, Gensol Engineering, Tata Power, etc.
The inspection covered the period from January 27 until January 31, 2025, and was used to assess cGMP and other regulatory requirements at the facility
Here are some of the stocks that may see significant price movement today: Bharti Airtel, Vedanta, Rail Vikas Nigam (RVNL), etc.
Ipratropium Bromide Nasal Solution (0.03%) is indicated for the symptomatic relief of rhinorrhea (runny nose) associated with allergic and nonallergic perennial rhinitis.
Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide tablets are therapeutic equivalents of Symtuza Tablets 800 mg/150 mg/200 mg/10 mg brand of Janssen Products, LP.
Here are some of the stocks that may see significant price movement today: Tata Motors, BHEL, Hindalco, Lupin, etc.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
